The most common side effects of vatiquinone reported in Friedreich’s ataxia clinical trials involved the gastrointestinal tract and included impaired taste, increased weight, and indigestion. It’s recommended that patients speak with their healthcare providers to understand how the medication may affect them. They should also report any unanticipated side effects… Read More
In clinical trials, significant benefits of vatiquinone, such as reduced face and neck (bulbar) symptoms, better upper limb coordination, and improved neurological function, were seen after six months. Because Friedreich’s ataxia has a variable disease course, some patients may see benefits earlier than others. More data is needed to… Read More
Because vatiquinone is still in the early stages of development, studies examining its interaction with alcohol are lacking. Patients who wish to drink alcohol while taking the medication should discuss this issue with their doctors. Read More
Vatiquinone is an experimental therapy that’s not yet approved for treating Friedreich’s ataxia (FA). It’s designed to limit neuroinflammation and nerve cell damage in people with FA by blocking the activity of an enzyme called 15-lipoxygenase. In clinical trials, this has led to significant reductions in disease progression. Read More
Vatiquinone is being investigated in the extension part of a Phase 2/3 trial in people with Friedreich’s ataxia as well as a Phase 2 study in children with the disease. While it’s shown promise in earlier trials, more data is needed to establish vatiquinone’s safety and efficacy. Therefore, it’s… Read More
The most common side effects associated so far with leriglitazone in clinical trials include swelling (edema) in the legs, face, or other areas, along with weight gain and increases in certain cardiac markers. These side effects are consistent with the known safety profile of PPAR-gamma agonists, the family of molecules… Read More
Leriglitazone is still in the early stages of clinical development, but existing clinical trial data didn’t find a benefit of the therapy in Friedreich’s ataxia (FA) patients over a year of treatment with respect to spinal cord atrophy (wasting), a measure that’s thought to correlate with clinical disease progression. Read More
Existing clinical trial data don’t mention an interaction between leriglitazone and alcohol, however, the treatment is still in early stages of development. More information is needed about leriglitazone’s potential interactions with other substances. Read More
An experimental therapy not yet approved for Friedreich’s ataxia (FA), leriglitazone is designed to increase cellular energy production, which is deficient in FA, thereby easing symptoms of the disease. Read More
A Phase 2 clinical trial testing leriglitazone in people with Friedreich’s ataxia has been completed, but it didn’t meet its main efficacy goal. Because the safety and efficacy of leriglitazone haven’t been fully established, it’s not known if or when the treatment will be approved in the U.S. Read More
As nomlafobuspis still in Phase 2 clinical testing, information about potential side effects associated with this therapy is still scarce. Available trial data in people with Friedreich’s ataxia indicate that mild to moderate reactions at the injection site were the most common side effects reported to date. Read More
Efficacy results of nomlafobusp in clinical trials are still scarce, so more data will be needed to have an indication of how soon patients may see benefits with treatment. Data from Phase 1 (NCT04519567) and Phase 2 (NCT05579691) trials suggest consistent increases in levels of frataxin, the protein… Read More
Existing information from clinical trials does not mention a possible interaction between alcohol and nomlafobusp. However, clinical testing of nomlafobusp is still in early stages, so more information about treatment interactions and side effects is needed. Read More
Nomlafobusp is an experimental therapy that is not yet approved for the treatment of Friedreich’s ataxia. It is designed to deliver a functional version of frataxin — a protein whose shortage causes Friedreich’s ataxia — to help improve the functionality of mitochondria, the so-called “powerhouses” of cells. This… Read More
Nomlafobusp is in the early stages of clinical testing and is currently undergoing an extension study of a completed Phase 2 trial in people with Friedreich’s ataxia. Read More
The most common side effects of Skyclarys are elevated levels of liver enzymes, headache, nausea, abdominal pain, fatigue, diarrhea, and musculoskeletal pain; such pain may affect bones, joints, ligaments, tendons, or muscles. The therapy’s prescribing information includes warnings about the risk of increased liver enzymes, high levels of B-type… Read More
In the Phase 2Â MOXIe trial (NCT02255435), whose results supported the approval of Skyclarys by the U.S. Food and Drug Administration, improvements in the function of mitochondria (the so-called powerhouses of cells) and in neurological function were most evident about three months (12 weeks) after starting Skyclarys treatment. Benefits were… Read More
There is no direct evidence reported of an interaction between alcohol and Skyclarys. Patients are, however, advised to talk to their healthcare providers about the use of alcohol or other substances while taking Skyclarys. Read More
Friedreich’s ataxia (FA) is characterized by dysfunction of mitochondria, which are the energy production centers in cells, chronic inflammation, and oxidative stress, a type of cell damage marked by overproduction of toxic reactive oxygen species that outweighs the body’s antioxidant defenses. Skyclarys is intended to activate NrF2, which stands… Read More
Skyclarys was approved by the U.S. Food and Drug Administration (FDA) in February 2023 for adults and adolescents, ages 16 and older, with Friedreich’s ataxia. The FDA’s approval made Skyclarys the first and only therapy for the disease in the U.S. Read More
A walker either has no wheels, or it has a pair of wheels on the front of the frame. It is intended for a person with a slow gait and balance issues and is designed to bear the weight of the person as they step. A rollator, on the other… Read More
While there aren’t any wheelchairs designed specifically for people with Friedreich’s ataxia, plenty of options are available for both manual and power chairs that address the needs of someone with the condition. Patients should check with a healthcare professional, such as an occupational therapist, who can evaluate their needs… Read More
The Original Medicare does not cover home adaptations, and though some Medicare Advantage plans may help cover certain home safety equipment, the support is still limited. In some U.S. states, Medicaid may help pay for certain home improvements. Some expenses — such as the cost for ramps,… Read More
Assistive equipment can help a person with Friedreich’s ataxia when dealing with symptoms such as difficulty walking, balancing, and communicating. Adaptive devices can also help reduce strain on the skeletal and cardiovascular systems, but will generally not reduce symptoms of the condition. Read More
Mobility aids can include canes, walkers, rollators, and wheelchairs. All are designed to maintain mobility and independence in people with balance issues and weakened muscles, such as those that occur with Friedreich’s ataxia. Read More
Lifestyle changes cannot eliminate Friedreich’s ataxia (FA) symptoms or prevent disease progression, but some alterations in day-to-day living may be helpful; for example, regular physical exercise can help patients maintain their motor function and ease fatigue. Dietary modifications may be helpful for patients who have difficulty chewing or swallowing, and… Read More
Insurance policy coverage varies depending on the specific insurer and plan. It’s recommended that people with Friedreich’s ataxia consult with their specific insurance provider to understand what forms of coverage are available for them. In the case of Skyclarys (omaveloxolone), the first and… Read More
Although there is no cure for Friedreich’s ataxia, a range of therapies are available that can help to ease symptoms, slow disease progression, and maintain to a certain extent a person’s functionality. In terms of medication, Skyclarys (omaveloxolone) is the only specific Friedreich’s… Read More
There is no cure for Friedreich’s ataxia; however, there are therapies available that can slow the disease’s progression and ease symptoms. Read More
Skyclarys (omaveloxolone) is the first therapy ever to be approved by the U.S. Food and Drug Administration (FDA) to treat Friedreich’s ataxia. Although Skyclarys is not a cure for the genetic disorder, the once-daily oral therapy has been proven to slow the progression of the disease in clinical trials. Read More
Get regular updates to your inbox.